VasoGenix Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
VasoGenix Pharmaceuticals Inc. is developing a naturally occurring cardioprotectant as a front-line treatment for myocardial infarction. Its calcitonin gene related peptide drug is designed not only to restore blood flow, but also to also actively protect cardiac tissue.